Injection site reactionsa
Injection site reactionsa
ADVERSE REACTIONS OCCURRING IN ≥1% OF PATIENTS TAKING DUPIXENT 300 mg Q2W +
INCS AND AT A HIGHER RATE THAN PLACEBO + INCS
SINUS-24 and SINUS-52
(24‑week safety pool)
DUPIXENT 300 mg
Q2W + INCS n=440 n (%)
Q2W + INCS n=440 n (%)
DUPIXENT 300 mg
Q2W + INCS n=440
n (%)
Q2W + INCS n=440
n (%)
Injection site reactionsa
28 (6%)
Conjunctivitisb
7 (2%)
Arthralgia
14 (3%)
Gastritis
7 (2%)
Insomnia
6 (1%)
Eosinophilia
5 (1%)
Toothache
5 (1%)
Placebo + INCS n=282 n (%)
Placebo + INCS n=282
n (%)
n (%)
Injection site reactionsa
12 (4%)
Conjunctivitisb
2 (1%)
Arthralgia
5 (2%)
Gastritis
2 (1%)
Insomnia
0 (<1%)
Eosinophilia
1 (<1%)
Toothache
1 (<1%)
aInjection site reactions cluster includes injection site reaction, pain, bruising, and swelling.
bConjunctivitis cluster includes conjunctivitis, allergic conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, giant papillary conjunctivitis, eye irritation, and eye inflammation.
In the safety pool, the proportion of subjects who discontinued treatment due to
adverse events was 2% in the DUPIXENT Q2W group and 5% in the placebo group1
The safety profile of DUPIXENT Q2W through Week 52 was generally consistent with the safety profile observed at Week 24.1
In subjects with CRSwNP, the frequency of conjunctivitis was 2% in the DUPIXENT group compared with 1% in the placebo group in the 24-week safety pool; these subjects recovered. There were no cases of keratitis reported in the CRSwNP development program.
In SINUS-52 (52 weeks), the frequency of conjunctivitis was 3% in the DUPIXENT group compared with 1% in the placebo group; all of these subjects recovered.1
Explore the
Study Designs
Dosage and Administration
See the recommended dosing and administration options for patients on DUPIXENT.